- Home
- MBBC vs BTAI Comparison
MBBC vs BTAI Comparison
Compare MBBC & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MBBC | BTAI |
|---|---|---|
| Founded | 1902 | 2017 |
| Country | United States | United States |
| Employees | 35 | 29 |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.2M | 35.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | MBBC | BTAI |
|---|---|---|
| Price | $14.02 | $1.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 18.3K | ★ 590.7K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.63 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $197.82 |
| Revenue Next Year | N/A | $910.15 |
| P/E Ratio | $47.11 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.95 | $1.01 |
| 52 Week High | $15.75 | $8.08 |
Technical Indicators
Market Signals| Indicator | MBBC | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 54.56 | 43.30 |
| Support Level | $12.90 | $1.05 |
| Resistance Level | $15.57 | $1.39 |
| Average True Range (ATR) | 0.54 | 0.09 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 77.72 | 10.14 |
Price Performance
Historical ComparisonAbout MBBC Marathon Bancorp Inc.
Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.